5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response

We would like to thank Maeda and colleagues for their letter regarding our article. They suggest that the dose of irinotecan should be escalated above 180 mg/m2 in patients with the UGT1A1 \*1/\*1 and \*1/\*28 genotypes. To support their view, they cited two studies that explored the safety and